Information Provided By: 
Fly News Breaks for May 8, 2019
GHDX
May 8, 2019 | 07:31 EDT
Canaccord analyst Mark Massaro reiterated a Buy rating on Genomic Health but trimmed his price target to $85 from $95 following the company's "solid" Q1 beat, saying Genomic holds unique qualities as a dominant industry leader in breast cancer recurrence testing. Massaro tells investors in a research note that he believes Genomic Health now appeals to growth, GARP and even value investors.
News For GHDX From the Last 2 Days
There are no results for your query GHDX
